Amanta Healthcare IPO: Key Details and Objectives for Fundraising

Amanta Healthcare Files Draft Papers with SEBI

Amanta Healthcare, a prominent pharmaceutical company, has initiated proceedings to raise capital through an initial public offering (IPO) by filing its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The proposed issue size is up to 1,25,00,000 equity shares with a face value of ₹10 each, fully comprising a fresh issue.

Purpose of the Amanta Healthcare IPO

The primary objectives of this IPO are to fund critical capital expenditures for civil construction projects, as well as the procurement of vital equipment, plant, and machinery specifically for establishing a new SteriPort manufacturing line in Hariyala, Kheda, Gujarat. Additionally, funding will support the development of a new Small Volume Parenteral (SVP) manufacturing line at the same facility and cover general corporate purposes.

Medical Innovations from Amanta Healthcare

Amanta Healthcare is known for its innovative approaches in the industry. Specializing in the production of sterile liquid products utilizing Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, the company’s offerings include large and small volume parenterals (LVPs and SVPs) across various therapeutic sectors such as fluid therapy, ophthalmics, and respiratory care.

With compliance to global GMP standards at its Gujarat facility, Amanta not only caters to domestic markets but exports products to 19 countries, supported by 113 active international product registrations. It also collaborates with other pharmaceutical firms to enhance production.

Broader Market Context

In a competitive landscape, Amanta Healthcare is preparing for significant growth opportunities alongside other companies like All Time Plastics and Dev Accelerator, who have also submitted their DRHPs to SEBI for upcoming IPOs.